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Structurally diverse hamigerans from the New Zealand
marine sponge Hamigera tarangaensis: NMR-directed
isolation, structure elucidation and antifungal activity†
A. Jonathan Singh,a Jonathan D. Dattelbaum,‡b Jessica J. Field,a Zlatka Smart,a
Ethan F. Woolly,a Jacqueline M. Barber,a Rosemary Heathcott,a John H. Millera and
Peter T. Northcote*a
The NMR-directed investigation of the New Zealand marine sponge Hamigera tarangaensis has aﬀorded
ten new compounds of the hamigeran family, and a new 13-epi-verrucosane congener. Notably, hamigeran F (6) possesses an unusual carbon–carbon bond between C-12 and C-13, creating an unprecedented skeleton within this class. In particular, the structural features of 6, hamigeran H (10) and
hamigeran J (12) imply a diterpenoid origin, which has allowed the putative biogenesis of three hamigeran carbon skeletons to be proposed based on geranyl geranyl pyrophosphate. All new hamigerans
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exhibited micromolar activity towards the HL-60 promyelocytic leukaemic cell line, and hamigeran G also

DOI: 10.1039/c3ob41305e

selectively displayed antifungal activity in the budding yeast Saccharomyces cerevisiae. Homozygous
deletion proﬁling (HOP) analysis suggests Golgi apparatus function as a potential target of this unusual

www.rsc.org/obc

class of sponge-derived terpenoids.

Introduction
Hamigera tarangaensis (Bergquist and Fromont, 1988) is a
poecilosclerid sponge found predominately around northern
New Zealand. The live sponge is orange-red to bright yellow
underwater with rippled exterior and large, tented oscules. The
first reported chemical study of H. tarangaensis, collected from
the Hen and Chicken Islands oﬀ the northeastern coast of the
North Island of New Zealand, resulted in the purported isolation of bromocyclooctane 1.1 Further examination of the
sponge identified the hamigerans—phenolic compounds with
varying degrees of bromination and cyclization.2 The structures
of the hamigerans were elucidated by NMR and X-ray
methods,3 which prompted the structural revision of 1 to hamigeran E (5). The reported biological activity of these compounds
range from mild cytotoxicity (P388 murine leukaemia cells) to
inhibition of herpes and polio viruses for hamigeran B (4). The
tricarbocyclic skeleton and reported biological activity of the
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hamigerans, in particular 4, has generated interest from synthetic organic chemists using a variety of approaches.4–14
Our work focused on a bright yellow sponge collected from
Cape Karikari in coastal waters oﬀ the northern North Island
of New Zealand that was subjected to an NMR-based screening
protocol and examined for the presence of secondary metabolites. Analysis of 1H and HSQC NMR spectra of the semipurified extracts acquired in CD3OD immediately presented a
combination of interesting signals, including aromatic protons
(δH 6.50–7.00, δC 120–130), deshielded methyl singlets
(δH 2.00–2.50, δC 20–25) and highly shielded methyl doublets
(δH 0.00–1.00, δC 20–25). In addition to these signals, proton
resonances in the δH 10.00–14.00 range were observed when
the 1H NMR spectra of the screening fractions were acquired
in CDCl3, indicative of hydrogen-bound exchangeables. Acid
digestion (HNO3) of the sponge material and examination of
the spicules (see ESI†) revealed unusually large, arcuate isochelae (average length: 52 µm) and strongyles (average dimensions: 357 × 7 µm) that matched the literature description for
H. tarangaensis.15 These data were correlated to the papers
published by Cambie and co-workers which revealed the hamigerans as the isolates present in this sponge. The combination
of NMR resonances mentioned above are consistent with those
proposed for this class of compounds. The use of conventional
isolation procedures, including size-exclusion chromatography
and C18 HPLC, led to the isolation of three known and eight
new members of the hamigeran family of compounds and a
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new 13-epi-neoverrucosane. Examination of a geographical
variant of this sponge using EtOH in place of MeOH aﬀorded
an additional two new hamigeran congeners and an ethylated
version of hamigeran A. The nature of these new hamigerans
shed light on the biogenesis of this structural class.

Results/discussion
Isolation and structure determination
Methanolic extracts of a Cape Karikari specimen of H. tarangaensis were separated using a series of reversed-phase techniques (PSDVB, Me2CO–H2O, MeOH–0.1 M HCOOH(aq)) and
LH-20 size-exclusion chromatography. Final HPLC purification
(C18, MeOH or MeCN–0.1–0.2 M HCOOH(aq)) aﬀorded new

compounds 6, 8, 10–12 and 15–17 alongside the known compounds hamigeran A (2),16 debromohamigeran A (3) and
hamigeran B (4), with 2 and 4 prevalent in most fractions.
A separate extraction of sponge material from Cavalli Island,
with EtOH replacing all instances of MeOH in the isolation
procedure, resulted in the isolation of compounds 13, 14 and
the ethyl ester variant of hamigeran A (as compound 19) alongside smaller quantities of the known methyl ester 2 (Chart 1).
Hamigeran F (6) was isolated as a colourless film. The positive ion HRESIMS for hamigeran F showed a pseudomolecular
[M + Na]+ ion at m/z 459.0781 (Δ = −0.4 ppm), giving a molecular formula of C21H25O5Br with nine degrees of unsaturation. Evidence of bromine came in the form of an equally
intense [M + 2 + Na]+ peak. The 1H, 13C and multiplicity-edited
HSQC NMR spectra in CDCl3 (Table 1) revealed that 23 of the

Chart 1
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Table 1

13

C (150 MHz) and 1H (600 MHz) NMR data for hamigeran F (6) in CDCl3

13

1

C

H

Position

δC

mult.

1
1-OH
2
3
4
4a
5
6
7
8

152.2

C

113.3
138.8
121.8
135.0
53.9
47.4
27.9
36.5

C
C
CH
C
CH
CH
CH2
CH2

58.3
202.9
79.3
81.0

C
C
CH
C

119.6
42.2
20.0
28.8
22.3
23.3
171.6
21.0

C
C
CH3
CH3
CH3
CH3
C
CH3

9
10
11
12
12-OH
12a
13
14
15
16
17
18
19
a

Paper

δH

mult. ( J, Hz)

8.97

br s

160

6.52

s

5(w), 17

1(w), 2, 3(w), 4a(w), 5, 12(w), 12a, 17

5, 16, 17

134
135
129
130a
133a

2.90
2.41
2.13
1.75
2.00

d (8.4)
td (8.7, 3.8)
m
m
ddd (14.5, 8.1, 6.7)

4(w), 6
5, 7
6, 8a, 8b
7, 8b
7, 8a

1(w), 4, 4a, 6, 9, 10, 12a, 13, 16
5, 8(w), 9, 12(w), 13
8(w), 9(w), 13
6(w), 7(w), 9, 10(w), 16(w)
5, 6, 10

4, 6, 7(w), 8a(w), 15(w), 16
5, 7, 14, 15
5(w), 6, 8a, 8b, 11, 14
5(w), 7, 8b, 16
7, 8a, 11, 14(w), 16(w)

145

5.71

s

10, 12, 12a, 13, 18

7, 8b, 14

3.76

br s

12(w), 12a(w), 13(w)

127
127
126
128

1.28
0.81
1.13
2.33

s
s
s
s

130

2.22

s

1

JCH (Hz)

COSY

HMBC

NOESY

1(w), 2(w), 12a(w)

15
14
4

6, 12, 13, 15
6, 12, 13, 14
5, 8, 9, 10
2, 3, 4, 12a

6, 7, 8b(w), 11, 15
5(w), 6, 14
4, 5, 8a, 8b(w)
4

11(w), 18

Estimated value due to distorted overlap.

25 protons were attached to 11 carbons, including: five
methyls (δC 28.8; 23.3; 22.3; 21.0; 20.0), two methylenes
(δC 36.5; 27.9) and four methines (δC 121.8; 79.3; 53.9; 47.4).
The remaining ten carbons were assigned as non-protonated
centres and included a ketone carbonyl (δC 202.9), an ester/
lactone carbonyl (δC 171.6), five olefinic/aromatic carbons
(δC 152.2; 138.8; 135.0; 119.6; 113.3) and three sp3 quaternary
carbons (δC 81.0; 58.3; 42.2). The nature of the five nonprotonated aromatic carbons and the lone aromatic methine
were consistent with the same phenolic moiety present in the
known hamigerans. The two remaining protons (δH 8.97; 3.76)
observed in the 1H NMR experiment were assigned as
exchangeable. With the evidence towards an aromatic ring and
two carbonyl centres, the remainder of the structure must
contain an additional three rings.
Further analysis of the 1D- and 2D-NMR data (Table 1) led
to the identification of three spin systems. The lone aromatic
methine (δC 6.52, δC 121.8, CH-4) and aromatic methyl
(δC 2.33, δC 23.3, CH3-17) were indicative of a pentasubstituted
benzene ring that was established through COSY and HMBC
correlations. The remainder of the structure was assigned
through COSY and HMBC correlations (Fig. 1) and chemical
shift comparisons with known hamigerans. The most significant change in this structure was the presence of a gemdimethyl group (δC 42.2, C-13; δH 1.28, δC 20.0, CH3-14;
δH 0.81, δC 28.8, CH3-15) in place of the usual isopropyl terminus—a new feature to this family of compounds. The
gem-dimethyl moiety formed part of a fourth carbocyclic
ring, as evidenced through a series of HMBC correlations
to C-6 (δC 47.4) and C-12 (δC 81.0). NOESY correlations

This journal is © The Royal Society of Chemistry 2013

Fig. 1 Key COSY and HMBC correlations establishing the planar structure of
hamigeran F (6).

between H-5, H-6 and H3-16 indicated the retention of relative
stereochemistry at these centres as observed in all other
hamigeran congeners. Additional correlations between H-11
(δH 5.71) and H3-14 placed these two groups on the same
face of the molecule (Fig. 2). These data present hamigeran
F as a new compound featuring a benzotricyclo[5.3.1.04,8]undecane core, a new feature in this family of compounds
and to our knowledge, an unprecedented natural product
skeleton.
Prolonged storage of 6 in CDCl3 led to the rearranged
product 7. The structure was assigned by direct comparison
with 6. The presence of a new, isolated oxymethylene (δH 4.11,
4.73; δC 67.0, CH2-11) along with a new phenolic hydroxyl
proton (δH 12.98, 1-OH) indicated a disconnection about the
C-11 to C-12 bond. A second ketone carbonyl resonance at δC
209.1, corresponding to C-12, gave further evidence towards

Org. Biomol. Chem., 2013, 11, 8041–8051 | 8043
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Key NOESY correlations establishing the relative stereochemistry of hamigeran F (6).

the change in structure. We propose that the formation of 7
from 6 is due to an acid-catalyzed retro-aldol conversion,
leading to cleavage of the C-11/C-12 σ-bond.
Hamigeran G (8), a pale-yellow amorphous solid, was
assigned a molecular formula of C19H23O3Br (HRESIMS,
[M + Na]+, m/z 401.0731, Δ = +1.5 ppm). All 1D- and 2D-NMR
spectra performed in CDCl3 consistently showed two sets of
resonances, despite exhaustive attempts at normal- and
reversed-phase purifications. Additionally, evidence of conformational exchange between the two species was observed in
the 2D NOESY of 8, suggestive of two solution conformers. All
19 carbon resonances of the major conformer of hamigeran G
were identified from analysis of the 1D- and 2D-NMR spectra
(Table 2 and ESI†); 11 of which were confirmed through a multiplicity-edited HSQC as protonated centres: four methyls (δC
31.9; 24.2; 22.4; 22.2), three methylenes (δC 53.5; 40.7; 31.4)
and four methines (δC 128.1; 60.8; 53.6; 29.9). The remaining
eight non-protonated centres were assigned across two carbonyls (δC 195.8; 190.8), five aromatic carbons (δC 160.4; 148.3;
141.9; 118.6; 113.2) and one sp3 quaternary carbon (δC 45.4).
This required the one hydrogen at δH 12.18 to be attached to
oxygen. Structure elucidation of the major compound followed
closely to other hamigeran congeners, with the pentasubstituted aromatic ring, isopropyl side-chain and angular methyl
all present in this structure. The key diﬀerence in this compound was the inclusion of an isolated methylene unit (δH
2.58, 2.71; δC 53.5, C-10) adjacent to a 1,2-diketone moiety at
C-11 (δC 195.8) and C-12 (δC 190.8).
Assignment of the relative configuration of hamigeran G
was achieved by analysis of 1H–1H coupling constants, NOESY
data and comparison with other hamigerans. With only three
centres to consider—C-5, C-6 and C-9—the assignments were

8044 | Org. Biomol. Chem., 2013, 11, 8041–8051

relatively simple to make. NOESY correlations between H-5
and H3-16 indicated the retention of the cis-fusion of the
bicyclo[5.3.0]decane. H-5 (d, 11.3 Hz) also correlated in this
fashion to H-6, suggestive of conserved relative stereochemistry
at these centres between 8 and other known hamigerans. It is
thought that the presence of a minor conformer of 8 is due to
the conformational flux of this diketone unit. In addition,
hamigeran G (8) also tautomerizes to the diosphenol 9, which
could be separated using reversed-phase HPLC and studied
with NMR (see ESI†) long enough to obtain data before reverting back to the diketo compound 8.
Hamigeran H (10) was isolated as a pale yellow/colourless
film. The molecular formula of C22H30O5 was determined
through HRESIMS ([M + Na]+, m/z 397.1995, Δ = +1.0 ppm). All
22 carbons and 30 protons were observed in the respective 13C
and 1H NMR spectra (Table 2 and ESI†), consistent with the
proposed molecular formula. The multiplicity-edited HSQC
experiment showed 14 protonated carbons, belonging to six
methyls (δC 30.0; 23.6; 22.0; 21.5; 20.9; 20.8), two methylenes
(δC 34.2; 31.3) and six methines (δC 129.4; 119.3; 80.0; 61.5;
53.1; 27.7). Of the remaining eight non-protonated carbons,
two were assigned as carbonyls (δC 202.9; 172.7), four aromatic
carbons (δC 158.4; 138.8; 135.0; 123.1), and two quaternary sp3
centres (δC 80.3; 47.9). In comparison to the previously
reported hamigerans, a tertiary methyl (δH 1.81, δC 22.0, CH318), an additional aromatic methine (δH 6.76, δC 119.3, CH-2)
and a saturated ketone at δC 202.9 stood out as the most
notable features of this compound. Construction of the planar
structure of 10 was made in the same fashion as the previous
compounds, with the placement of CH3-18 established by way
of HMBC correlations to C-11, carbinol C-12 (δC 80.3), C-12a,
and a COSY correlation with 12-OH (δH 4.70).

This journal is © The Royal Society of Chemistry 2013
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Table 2

1

H (600 MHz) and 13C (150 MHz) NMR data for isohamigerane-derived compounds 8, 10, 11, 16, and 17 in CDCl3

8a
δC
Position mult.
1
1-OH
2
3
4
4a
5
6
7

160.4 C

8

40.7 CH2

10
δH mult.
( J, Hz)

δC
mult.

10-OH
11
11-OH
12
12-OH
12a
13
14
15
16
17
18
19
20
a

11
δH mult.
( J, Hz)

158.4 C

16
δH mult.
( J, Hz)

δC
mult.
160.9 C

12.18 s

8.84 s
113.2 C
119.3 CH 6.76 d (1.2)
148.3 C
138.8 C
128.1 CH 6.78 s
129.4 CH 6.55 s
141.9 C
135.0 C
60.8 CH 3.39 d (11.3)
61.5 CH 3.51 d (11.4)
53.6 CH 2.01 m
53.1 CH 1.90 m
31.4 CH2 1.16 qd (13.0, 6.5) 31.3 CH2 1.11 qd (13.0, 6.3)
1.74 m
1.59 m
1.62 td (13.2, 6.7)

34.2 CH2

1.98 m
9
10

Paper

45.4 C
53.5 CH2

2.58 d (12.0)
2.71 d (12.0)

1.28 m

195.8 C

202.9 C

190.8 C

80.3 C

5.15 s

δH mult.
( J, Hz)

δC
mult.

159.0 C

156.7 C

112.3 C
144.6 C
123.6 CH
144.2 C
50.1 CH
51.6 CH
28.8 CH2

111.8 C
143.4 C
123.2 CH
141.7 C
52.9 CH
51.7 CH
29.1 CH2

δH mult.
( J, Hz)

13.30 s
113.6 C
148.2 C
128.4 CH
141.9 C
61.2 CH
53.9 CH
32.5 CH2
34.6 CH2

2.27 m
47.9 C
80.0 CH

δC
mult.

17

6.77 s

3.44 d (11.7)
2.22 m
1.58 m
1.92 dddd
(16.3, 13.9, 8.1, 2.6)
1.42 m
38.7 CH2
2.57 ddd
(13.6, 7.2, 2.5)

47.9 C
74.45b CH 3.32 d (10.8)
4.15 br s
74.43b CH 4.59 d (10.8)
3.17 br s
204.9 C

47.2 C
42.4 CH2

6.56 s
4.55 d (6.9)
2.34 m
1.64 m
2.16 m

1.57 ddd
37.9 CH2
(12.4, 9.9, 2.1)
1.77 td
(12.5, 7.5)
46.2 C
1.83 d (15.5)
43.4 CH2
2.06 d (15.3)

180.0 C

174.8 C

177.3 C

172.1 C

6.53 s
3.87 d (7.2)
2.23 m
1.64 m
2.08 m
1.78 m
1.92 m
2.02 d (15.1)
2.38 d (15.1)

4.70 s
118.6 C
29.9 CH
22.2 CH3
22.4 CH3
31.9 CH3
24.2 CH3

0.84 m
0.69 d (6.5)
0.25 d (6.5)
1.29 s
2.48 s

123.1 C
27.7 CH
21.5 CH3
23.6 CH3
30.0 CH3
20.9 CH3
22.0 CH3
172.7 C
20.8 CH3

0.96 m
0.70 d (6.3)
0.61 d (6.8)
1.30 s
2.26 s
1.81 s

116.3 C
29.6 CH
22.1 CH3
23.5 CH3
30.1 CH3
24.0 CH3

1.10 m
0.77 d (6.6)
0.20 d (6.1)
1.25 s
2.45 s

113.1 C
30.7 CH
22.5 CH3
22.0 CH3
27.7 CH3
24.6 CH3

1.40 m
0.91 d (6.5)
0.69 d (6.4)
1.31 s
2.45 s

115.4 C
30.1 CH
22.3 CH3
22.2 CH3
28.2 CH3
24.5 CH3
51.9 CH3

1.12 m
0.82 d (6.5)
0.63 d (6.4)
1.25 s
2.43 s
3.59 s

2.16 s

Major conformer. b Interchangeable.

The completed planar structure of hamigeran H (10) contains five stereogenic centres. Diagnostic NOESY correlations
between H-5, H-6 and H3-16 indicated retention of the relative
stereochemistry of these centres, consistent with the other
hamigeran compounds. These conserved correlations also
established the relationship of the two new stereocentres
CH-10 and C-12, leading to the relative stereochemistry shown.
Through-space correlations observed between H-10 and H3-16
implies a cis relationship and places H-10 on the same
(convex) face as H-5 and H-6. For C-12, a set of NOESY correlations between methyl H3-18 and the C-13–C-15 isopropyl
group means that they occupy the concave face.
The molecular formula of hamigeran I (11) was established
as C19H25O4Br through analysis of its [M + Na]+ pseudomolecular ion (HRESIMS, m/z 419.0837, Δ = +0.7 ppm). NMR evidence
of all 19 carbons and 25 protons (Table 2 and ESI†) led to the
planar structure with a hydrogen-bonded phenolic hydroxyl
proton at δH 13.30 and an α,β-unsaturated ketone (δC 204.9)
among the diagnostic features for this compound. With the
majority of the constitutional structure of 11 being similar to
other congeners, the most relevant structural aspect of this
compound was the vicinal diol occupied by positions CH-10
(δH 3.32, δC 74.45) and CH-11 (δH 4.59, δC 74.43). In assigning
the relative stereochemistry of 11, a set of NOESY correlations
between H-5, H-6 and H3-16 validated the typically observed

This journal is © The Royal Society of Chemistry 2013

cis-fusion of the bicyclo[5.3.0]decane and orientation of the
isopropyl group. The trans relationship between H-10 and H-11
was established by vicinal coupling constants (3JHH = 10.8 Hz)
and supported by respective NOESY correlations between H-10
and H3-16, and H-11 with H-13.
Hamigeran J (12), with a molecular formula of C20H25O5Br
(HRESIMS, [M + Na]+, m/z 447.0786, Δ = +0.7 ppm), is isomeric
with hamigeran A (2). At first glance, spectroscopic data for 12
strongly resembled that of hamigeran A (2). Evidence of a
methyl ester (δC 170.6, C-17; δH 3.74, δC 53.8, CH3-18) and the
observation that most of the 13C and 1H NMR chemical shifts
(Table 3 and ESI†) were in close match with 2 confirmed this
assumption and allowed most of the structure to be assigned
through direct comparison. However, the absence of an
1
H NMR resonance attributed to a hydrogen-bonded phenolic
proton and an HMBC correlation from CH3-16 (δH 1.31) to a
signal at δC 210.1 (C-10) placed a saturated ketone adjacent to
the tertiary methyl, rather than an α,β-unsaturated ketone adjacent to the aromatic ring as observed in 2 (δC 198.1, C-12).
NOESY correlations observed between H-5, H-6 and H3-15,
along with a diagnostic through-space correlation between
H3-15 and H3-18, confirms that hamigeran J (12) is a regioisomer of hamigeran A (2).
Hamigeran K (13, C18H23O3Br), 10-epi-hamigeran K (14,
C18H23O3Br) and 4-bromohamigeran K (15, C18H22O3Br2)

Org. Biomol. Chem., 2013, 11, 8041–8051 | 8045

Paper
Table 3

Organic & Biomolecular Chemistry
1

H (600 MHz) and 13C (150 MHz) NMR data for hamigerane-derived compounds 12–15

12

13

Position

δC mult.

1
1-OH
2
3
4
4a
5
6
7

151.8 C

8

35.6 CH2

9
10
10-OH
11
11a
12
13
14
15
16
17
18

55.2 C
210.1 C

50.4 C
73.7 CH

76.8 C
120.0 C
27.5a CH
20.1 CH3
23.4 CH3
25.9 CH3
23.6 CH3
170.6 C
53.8 CH3

204.2 C
113.8 C
28.4 CH
23.6 CH3
17.7 CH3
19.7 CH3
24.4 CH3

a

δH mult. ( J, Hz)

δC mult.

14
δH mult. ( J, Hz)

158.1 C

δC mult.

6.78 s
3.34 d (9.0)
2.16 tt (14.0, 7.4)
1.62 m
1.72 m
1.45 dt (13.2, 8.0)
2.56 ddd (13.3, 7.3, 6.2)

1.37 m
0.54 d (6.6)
0.45 d (6.6)
1.31 s
2.42 s

110.8 C
148.1 C
124.5 CH
142.4 C
52.2 CH
48.0 CH
24.8 CH2
36.0 CH2

δH mult. ( J, Hz)

156.6 C
12.22 s

112.0 C
139.7 C
125.0 CH
136.6 C
57.0 CH
51.2 CH
27.4a CH2

15
δC mult.
157.8 C
11.63 s

6.66 s
3.13 d (12.3)
2.64 m
1.77 m
1.86 m
1.46 m
2.23 dd (13.1, 6.5)

110.8 C
147.3 C
123.1 CH
140.2 C
50.5 CH
53.6 CH
28.0 CH2
31.9 CH2
44.5 C
78.1 CH

4.43 s
3.47 br s
1.81 m
0.81 d (6.8)
0.43 d (6.8)
1.00 s
2.46 s

202.7 C
115.5 C
26.9 CH
23.6 CH3
21.9 CH3
28.6 CH3
24.6 CH3

δH mult. ( J, Hz)

6.73 s
3.20 d (6.1)
2.01 m
0.71 m
1.66 m
1.36 m
1.64 m
4.25 br s
3.67 br s
1.49 m
1.18 d (6.3)
0.79 d (6.6)
1.43 s
2.46 s

12.62 s
112.7 C
148.2 C
119.3 C
142.7 C
54.9 CH
46.4 CH
24.2 CH2
36.0 CH2

3.33 d (12.2)
2.93 m
1.73 m
1.92 m
1.46 m
2.25 m

50.6 C
73.0 CH

4.49 s

204.9 C
114.7 C
28.7 CH
23.5 CH3
18.1 CH3
19.4 CH3
26.4 CH3

1.66 m
0.80 d (6.9)
0.47 d (6.8)
0.98 s
2.73 s

3.74 s

Interchangeable.

were all identified as C-10 reduced forms of hamigeran B (4)
and 4-bromohamigeran B, respectively, with the structures
of all three compounds resolved by direct comparison with
their parent compounds (Table 3 and ESI†). Analysis of the
HRESIMS molecular ion clusters confirmed the presence of a
single bromine in 13 and 14 ([M + Na]+, m/z 389.0724/
389.0726, Δ = −1.0/−0.5 ppm), and two bromine atoms in 15
([M + Na]+, m/z 466.9833, Δ = 0.0 ppm). For all three compounds, COSY and HMBC correlations established aromatic
and aliphatic spin systems in accordance with the sequence
observed for the (4-bromo)hamigeran B framework. The
relative stereochemistry about the CH-10 oxymethine for
compounds 13 and 15 were both established by longrange w-coupling between H-10 and H3-15, indicative of a
1,2-diaxial relationship. By default, 10-epi-hamigeran K (14)
was assigned the opposite relative stereochemistry for this
position.
The molecular formulae for hamigeran L (16), C19H25O5Br,
and its methyl ester 17, C20H27O5Br, were both determined
from HRESIMS ([M + Na]+, m/z 435.0784 and 449.0933, respectively). Analysis of 1D- and 2D-NMR data for both compounds
(Table 2 and ESI†) quickly led to the identification of their
structures as homologues of hamigeran E (5). The two compounds mirrored hamigeran E in their planar structures, with
the exception of an isolated, diastereotopic methylene centre
at C-10. In the case of 17, placement of the methyl ester was
achieved by way of an HMBC correlation from H3-18 (δH 3.59)
to C-11 (δC 174.8). As hamigeran E can be rationalized as an
oxidation product of hamigeran B (4), the corollary can be
assumed with 16 and 17 to hamigeran G (12).
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Taking into account the stereochemical features of the
known hamigerans, for which the absolute configuration of
hamigerans A and B have been verified by X-ray and total synthesis, assignment of absolute configuration for the new hamigeran structures reported in this study are implied as drawn.
Specifically, the absolute configuration of hamigeran F (6) is
proposed to be 5R,6S,9R,11R,12S.
In the process of isolating compounds 6–12, a new, unrelated compound was isolated. 12-Acetoxy-13-epi-neoverrucosan-5-one (18), isolated as a colourless film, was identified
with a molecular formula of C22H34O3 (HRESIMS, [M + Na]+,
m/z 369.2401, Δ = −1.4 ppm). All 22 carbons and 34 protons
were accounted for in the 1H, 13C and HSQC NMR spectra;
whereas, evidence of the three oxygens was found in a saturated ketone at δC 211.4 and an acetate moiety (δH 2.05;
δC 21.6, 170.6). The remaining four double bond equivalents
were therefore satisfied through four rings. Standard elucidation procedures provided the planar structure of three rings,
while an additional HSQC experiment, optimized for 1JCH =
170 Hz, enhanced one methylene and one methine unit that
appeared weakly in the default experiment (1JCH = 140 Hz).
COSY evidence from these two centres and HMBC correlations
from H3-18 formed a structure consistent with a cyclopropane
moiety, thereby satisfying the fourth unsaturation. With the
planar structure of 18 complete, 1D- and 2D-NOESY experiments set the relative stereochemistry as shown. In CDCl3,
severe second-order eﬀects observed between H-1 and H-14
prevented unequivocal proof of their direct connection and
stereochemical relationship—only through changing solvents
to C6D6 was a trans relationship observed (3JHH ∼ 12.0 Hz)
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between the two centres. From these data, the structure of
compound 18 was assigned as a 13-epi-neoverrucosane.
Proposed biogenesis
The original report of the hamigerans did not comment on the
possible biogenetic origins of the compounds. The structures
of hamigerans F (6), H (10) and J (12) are consistent with a
diterpene precursor, which enables us to propose a biogenetic
pathway previously lacking in the literature. If a terpenoid
origin is considered, the hamigerans can be divided into two
distinct carbon skeletons emanating from geranyl geranyl pyrophosphate (GGPP)—termed here as hamigerane and isohamigerane (Fig. 3), in which the B ring is a six- or seven-membered
ring, respectively. In the case of hamigeran F (6), a third neohamigerane skeleton exists. All compounds derived from either
skeleton are norditerpenoids (or bis-norditerpenoids as with 4)
with the exception of hamigeran H (10), which has its full
complement of carbons. Structural features conserved
throughout all hamigeran compounds are the phenol moiety,
an unmodified cyclopentane, the cis-fusion of the B and C
rings, the relative stereochemistry of C-10 and C-11 in the isohamigeranes, and the presence and orientation of the methyl
esters in hamigerans A (2) and J (12). These are all significant
markers when postulating a biogenetic pathway for these
compounds.
Scheme 1 shows a proposed biogenetic pathway to the
hamigerans from GGPP as the acyclic precursor. The carbon
numbering system used here is based on GGPP and should
not be confused with the system used for the final compounds. A series of allylic oxidations at C-5, C-8 and C-9, followed by an E/Z-isomerization would facilitate the formation
of the aromatic A ring, while placing the phenolic hydroxyl
group at the correct position (C-5). In this proposed biogenesis, the order of cyclization is important. If the cyclopentane
ring is formed first, there is no allylic centre available for oxidation. A cascade cyclization forms the internal cyclohexyl B

Fig. 3 Hamigeran skeletons derived from geranyl geranyl pyrophosphate
(GGPP).
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ring and cyclopentyl C ring, promoted by the capture of an
electrophile (X), such as a proton or bromonium ion. Alternatively, the system is primed for a 6π disrotatory electrocyclic
closure in which, while aromaticity is initially lost, the second
cascade restores aromaticity and gives the same tricyclic
product. Removal of pyrophosphate (OPP) from C-1 forms the
relatively unstable primary carbocation that can be stabilised
by delocalisation of the C-3/C-17 methylidene.17 This can then
rearrange via either 1,2-hydride or 1,2-alkyl shifts to give the
hamigerane ( pathway a) or isohamigerane ( pathway b) carbon
skeletons, respectively. A more detailed sequence is provided
in the ESI.† The occurrence of both hamigeran A ethyl ester (19)
and 2 from the EtOH extraction of H. tarangaensis, verified by
1
H NMR and LCMS evidence, is consistent with our proposed
biogenesis and suggests the free acid is produced by the
sponge, with 2, 3 and possibly 12 existing as both artefacts of
isolation and as naturally occurring compounds.
In order to rationalize the existence of the neohamigerane
skeleton, a σ-bond must form between C-3 and C-15, which
could be made possible through a number of pathways. Enzymatic abstraction of isopropyl methine H-15, performed in a
manner similar to that required for the earlier cascade
sequence, may provide a route to bond formation with the C-3
ketone. Alternatively, if the electrophile captured earlier in
the sequence was a bromonium ion rather than a proton,
bond formation could occur via a metal-initiated mechanism,
e.g. an enzymatic Barbier-type reaction. The aforementioned
oxidation of C-17 to a carboxylic acid and subsequent decarboxylation may also provide impetus for this unusual bond
formation.
Biological activity
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) cell proliferation assays revealed that hamigerans F–J
were moderately cytotoxic towards the HL-60 (human promyelocytic leukaemic) cell line (Table 4). Hamigeran F (6) was
among the more cytotoxic of these new compounds, with an
IC50 value of 4.9 ± 1.2 µM; and its rearrangement product 7
was similar in potency (IC50 7.4 ± 1.9 µM). Hamigeran G (8)
exhibited the greatest cytotoxicity of these newly isolated compounds with an IC50 value of 2.5 ± 0.2 µM; whereas the potencies of compounds 10–17 ranged between 5.6–78.3 µM. The
cytotoxicities of known compounds 2–4 obtained in this study
correlate closely to those exhibited by the new compounds and
are comparable to the values initially reported against the
P388 cell line.2 Hamigerans F–J were also tested in cell cycle
arrest assays by flow cytometry, with all five compounds
showing a slight increase of cell accumulation at the G2/M
checkpoint, indicative of an antimitotic action. 12-Acetoxy-13epi-neoverrucosan-5-one (18) was ineﬀective towards HL-60 cell
cycle progression at concentrations of up to 50 µM.
The level of cytotoxicity displayed by hamigeran G (8) in the
MTT proliferation assay, coupled with access to enough of the
natural product, led us to initiate further studies in other biological systems. Because of the ease of genetic manipulation
and rapid turnover time in yeast, we tested hamigeran G for its
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Scheme 1

Table 4

Possible biogenesis of the hamigerane, isohamigerane and neohamigerane skeletons, derived from geranyl geranyl pyrophosphate (GGPP).

Hamigeran IC50 values (HL-60, n = 3 replicates)

Compound

Mean IC50 ± SEM (µM)

Hamigeran A (2)
Debromohamigeran A (3)
Hamigeran B (4)
Hamigeran F (6)
Hamigeran F rearrangement product (7)
Hamigeran G (8)
Hamigeran H (10)
Hamigeran I (11)
Hamigeran J (12)
Hamigeran K (13)
10-epi-Hamigeran K (14)
4-Bromohamigeran K (15)
Hamigeran L (16)
Hamigeran L 11-O-methyl ester (17)

16.0 ± 4.5
12.5 ± 3.4
3.4 ± 0.4
4.9 ± 1.2
7.4 ± 1.9
2.5 ± 0.2
16.5 ± 1.4
37.2 ± 1.4
48.2 ± 1.2
13.7 ± 0.6
28.5 ± 1.6
5.6 ± 0.4
78.3 ± 0.5
21.1 ± 3.3

ability to inhibit the growth of the budding yeast Saccharomyces cerevisiae, as this would allow us to screen for genes
involved in its mode of action.18 Chemical genomic screens
were carried out to gain insight into the genetic pathways
involved in the growth inhibition by hamigeran G. We used a
yeast strain deficient in drug eﬄux pumping activity to maximise the eﬀect of hamigeran G in the cell. We also repeated
the screen in a homozygous diploid yeast strain with normal
eﬄux pump activities. Hamigeran G inhibited growth of both
strains with IC50 values of 6.7 μM and 16.5 μM, respectively.
For each screen, a pool of deletion mutants were grown in the
presence of hamigeran G at a concentration that gave a 20%
reduction in growth. We then identified individual deletion
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mutants for each non-essential gene that showed reduced
growth, using a barcode microarray method as previously
described.19 The genes that were linked to hamigeran G were
then analysed using Funspec (http://funspec.med.utoronto.ca/).
Genes associated with the Golgi apparatus and Golgi vesicle
transport of proteins were particularly highlighted in the interactive networks. Genes involved in vesicle-mediated transport
included SNC1, SFT2, ARL1, GET3, SEC22, GYP1, RUD3; intraGolgi vesicle-mediated transport included COG7, COG8,
COG6, COG5; vesicle fusion included SNC1,GOS1, SEC22;
Golgi to plasma membrane protein transport included ARL1,
SYS1; ER to Golgi vesicle-mediated transport included GOS1,
SEC22, RUD3. Of the 13 Golgi transport-related genes identified in the drug eﬄux pump knockout strains (1n screen), nine
were also significant hits in the non-pump knockout, homozygous deletion strains (2n screen). In a single screen with the
eﬄux pump knockout strain, hamigeran B (4), which showed
little inhibitory activity on growth of this strain, was aﬀected
by deletion of only two of the 13 Golgi-related genes identified
with hamigeran G, specifically RUD3 and SFT2. Our results
suggest that hamigeran G may target the sorting and transport
of proteins within the Golgi network of the cell.

Conclusion
An NMR-guided investigation of the New Zealand marine
sponge Hamigera tarangaensis has resulted in the isolation of
several structurally diverse hamigerans, from which a unified
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diterpenoid biogenesis has been proposed. Hamigeran F (6),
with its unusual tetracyclic core, may be an interesting synthetic target. The selective antifungal activity displayed in yeast
by hamigeran G (8) is also intriguing. With access to larger
quantities of known and new hamigerans, particularly hamigerans B (4) and G (8), further studies have been undertaken
to decipher the mode of action of this family of compounds.

Experimental
General
NMR spectra were recorded using a Varian DirectDrive
600 MHz spectrometer, equipped with a HCN triple resonance
cryogenic probe. Chemical shifts (δ, ppm) were referenced to
the residual solvent peak.20 High-resolution mass spectra were
measured using a Waters Q-TOF Micromass Premier spectrometer. Optical rotations were measured using Rudolph
Autopol II or Perkin-Elmer 241 polarimeters. UV spectra were
recorded on a dual-beam spectrophotometer. HPLC was performed using a Varian PrepStar 210 solvent delivery module
with 100 mL pump heads ( preparative scale), or a Rainin
Dynamax SD-200 solvent delivery system with 25 mL pump
heads (semi-preparative and analytical scale). UV/vis detection
for HPLC runs was obtained with a Varian Prostar 335 photodiode array detector. Solvents used for flash normal- and
reversed-phase column chromatography are of HPLC or
analytical grade quality. All other solvents were purified by
distillation before use. Solvent mixtures are reported as
% vol/vol unless otherwise stated.
Animal material
Sponges were collected by hand using SCUBA at Cape Karikari
and Cavalli Island, New Zealand in 2003. Specimens were
stored at −20 °C until extraction. Voucher samples are stored
at the School of Chemical and Physical Sciences, Victoria
University of Wellington. Spicule analysis using SEM and
comparison with literature21 concluded that the sponge was
H. tarangaensis.
Extraction and isolation
Hamigeran F. Frozen Hamigera tarangaensis (PTN2_66E,
124.7 g), collected from Cape Karikari, New Zealand, was
extracted twice with MeOH (400 mL). The second, then first
extracts were loaded on an 80 mL HP20 column, pre-equilibrated in MeOH. The loaded column was then washed with
250 mL portions of (i) H2O, (ii) 30% Me2CO–H2O (fraction A),
(iii) 75% Me2CO–H2O (fraction B), and (iii) Me2CO (fraction
C). A 376.7 mg subsample of fraction B was fractionated on
silica gel (70 mL), eluting with 200 mL portions of 50%
hexanes–CH2Cl2 (fraction D), followed by EtOAc–CH2Cl2
(0–100%, fractions E1–172). Fractions E42–54 (1–2% EtOAc–
CH2Cl2) were combined and loaded on to a 20 mL column of
HP20SS and eluted with 60 mL portions of MeOH–H2O
(20–100%, fractions G–M). The 80–90% MeOH–H2O fractions
(K and L) were combined and purified using HPLC (C18, 90%
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MeOH–0.1 M HCOOH(aq)), giving hamigeran F (6, tR 7.3 min,
2.6 mg). The mixture of hamigeran F and its rearrangement product was separated by C18 HPLC (85% MeOH–
0.2 M HCOOH(aq)), which aﬀorded the latter compound
(7, tR 12.0 min, 0.4 mg) as a colourless film.
Hamigerans G–J, 4-bromohamigeran K, hamigeran L, hamigeran L 11-O-methyl ester and 12-acetoxy-13-epi-neoverrucosan-5-one. A second, separate sample of H. tarangaensis
(PTN2_66E, 266 g frozen weight) was cut into small pieces and
extracted with MeOH (2 × 1.5 L) for 24 h. The second, then
first extracts were passed through a 1 L column of HP20
PSDVB beads, pre-equilibrated in MeOH. The combined eluent
was diluted with H2O (3 L) and passed back through the
column. This eluent was again diluted with H2O (6 L) and
passed again through the column. The loaded column was
then washed with H2O (3 L) followed by 3 L portions of (i) 20%
Me2CO–H2O (fraction A), (ii) 40% Me2CO–H2O (fraction B),
(iii) 60% Me2CO–H2O (fraction C), (iv) 80% Me2CO–H2O (fraction D), (v) Me2CO (fraction E). A 600 mg portion of the 80%
Me2CO–H2O fraction was loaded on to a 20 mL column of
HP20SS PSDVB beads, placed on top of another HP20SS
column (350 mL), and eluted with increasing concentrations
of MeOH in 0.1 M HCOOH(aq) (75–100%). Thirty-eight fractions (100 mL each) were collected, and combined as follows:
(i) 1–7 (fraction F), (ii) 8–12 (fraction G), (iii) 13–19 (fraction
H), (iv) 20–22 (fraction I), (v) 23–27 (fraction J), and (vi) 28–38
(fraction K). Fraction G (56.2 mg) was subjected to C18 HPLC
(75% MeOH–0.2 M HCOOH(aq)), giving seven fractions (L–R).
Fraction M (12.9 mg) was again subjected to C18 HPLC
(65% MeCN–0.2 M HCOOH(aq)), resulting in another ten
fractions (S–AB), where fractions V and X gave hamigerans I
(11, tR 14.4 min, 0.4 mg) and J (12, tR 16.5 min, 3.1 mg),
respectively.
C18 HPLC (80% MeCN–0.2 M HCOOH(aq)) purification of
fraction N (7.6 mg) generated fractions AC–AF, from which
fraction AD gave debromohamigeran A (3, tR 10.1 min,
1.4 mg), while fraction AE aﬀorded 12-acetoxy-13epi-neoverrucosan-5-one (18, tR 10.8 min, 1.9 mg). Fraction O
(4.0 mg) was also purified further with C18 HPLC (70%
MeCN–0.2 M HCOOH(aq)), giving four fractions (AG–AJ), where
fraction AH resulted in hamigeran H (10, tR 16.0 min, 1.1 mg).
Fraction K (111.7 mg) was further purified using HPLC (C18,
75% MeOH–0.2 M HCOOH(aq)), aﬀording ten fractions (AK–
AT). Fractions AO and AQ gave hamigerans B (4, tR 34.9 min,
14.3 mg) and A (2, tR 58.3 min, 16.3 mg), respectively. Fractions
AP and AS aﬀorded hamigeran G (8, tR 39.8 min, 22.0 mg) and
hamigeran G enol (9, tR 67.3 min, 4.8 mg).
The remaining amount of fraction D (approx. 1.5 g) was
separated on LH-20 using 50% MeOH–CH2Cl2 as the running
solvent. TLC and 1H NMR analysis yielded a 185 mg hamigeran-enriched fraction, purified further using semi-preparative C18 HPLC (75–100% MeOH–0.2 M HCOOH(aq)) into 15
fractions AX–BK. From this, 4-bromohamigeran K (15, tR
79.9 min, 0.8 mg) was present in fraction BJ. Fractions AZ and
BC were individually purified further using analytical C18
HPLC (70% MeOH–0.2 M HCOOH(aq)) to give hamigeran L
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(16, tR 30.3 min, 4 mg) and hamigeran L 11-O-methyl ester (17,
tR 56.1 min, 1.4 mg), respectively.
Hamigeran K, 10-epi-hamigeran K and hamigeran A ethyl
ester. A frozen sample of Hamigera tarangaensis (PTN2_79F,
25 g), collected from Cavalli Island, New Zealand, was
extracted with EtOH (2 × 100 mL) and fractionated from
PSDVB (30 mL, pre-equilibrated in EtOH) with 100 mL portions of (i) 20% Me2CO–H2O, (ii) 40% Me2CO–H2O, (iii) 60%
Me2CO–H2O, (iv) 80% Me2CO–H2O and (v) Me2CO. The 80%
Me2CO–H2O fraction was separated on LH-20 using 50%
EtOH–CH2Cl2 as the running solvent. Hamigeran-containing
fractions, identified by TLC and 1H NMR analysis, were pooled
together and purified using semi-preparative C18 HPLC (75%
MeOH–0.2 M HCOOH(aq)) to give 13 fractions. Fraction 5
aﬀorded hamigeran K (13, tR 33.8 min, 0.5 mg), while fraction
8 was subjected to analytical (70% MeOH–0.2 M HCOOH(aq))
C18 HPLC to give 10-epi-hamigeran K (14, tR 69.9 min,
0.3 mg). Fraction 7 contained trace amounts of hamigeran A
(2) observable by 1H NMR. Fraction 10 aﬀorded hamigeran A
ethyl ester (19, tR 59.1 min, 1.5 mg). A sample of the hamigeran-containing fraction from LH-20 purification was subjected to LCMS analysis (C18, 3.5 μ, 2.1 × 30 mm, 5–100%
MeCN–0.5 mM NH4+HCOO−(aq), 14.5 min ramp time), where
hamigeran A (2, 9.8 min, [M + Na]+, Δ = –1.7 ppm) and hamigeran A ethyl ester (19, 10.3 min, [M + Na]+, Δ = +0.4 ppm)
were detected.
Hamigeran A (2). Yellow film/needles; [α]25
D −33° (c 1.1,
CH2Cl2); UV (MeOH) λmax 224 nm (ε 14 700), 282 nm (ε 9900),
344 nm (ε 4100); HRESIMS, [M + Na]+, observed m/z 447.0786,
calculated 447.0783 for C20H25O579BrNa, Δ = +0.7 ppm; all
other data as previously described.2,16
Debromohamigeran A (3). Pale yellow film; [α]25
D −104°
(c 0.09, CH2Cl2); UV (MeOH) λmax 221 nm (ε 19 700), 278 nm
(ε 16 000), 340 nm (ε 5800); HRESIMS, [M + Na]+, observed
m/z 369.1674, calculated 369.1678 for C20H26O5Na, Δ =
−1.1 ppm; all other data as previously described.2
Hamigeran B (4). Fine yellow needles; [α]25
D −104° (c 0.9,
CH2Cl2); UV (MeOH) λmax 283 nm (ε 5300), 310 nm (ε 4600);
HRESIMS, [M + Na]+, observed m/z 387.0579, calculated
387.0572 for C18H21O379BrNa, Δ = +1.8 ppm; all other data as
previously described.2
Hamigeran F (6). Colourless film; [α]25
−21° (c 0.05,
D
CH2Cl2); UV (HPLC, 85% MeOH–0.2 M HCOOH(aq)) λmax
220 nm (rel. int. 1), 337 nm (rel. int. 0.32); NMR data see
Table 1; HRESIMS, [M + Na]+, observed m/z 459.0781, calculated 459.0783 for C21H25O579BrNa, Δ = −0.4 ppm.
Hamigeran F rearrangement product (7). Colourless film;
[α]25
D +76° (c 0.04, CH2Cl2); UV (MeOH) λmax 228 nm (ε 9100),
273 nm (ε 4500), 338 nm (ε 2700); NMR data see ESI;†
HRESIMS, [M + Na]+, observed m/z 459.0776, calculated
459.0783 for C21H25O579BrNa, Δ = −1.5 ppm.
Hamigeran G (8). Yellow film; [α]25
D −131° (c 0.05, CH2Cl2);
UV (MeOH) λmax 272 nm (ε 2000), 327 nm (ε 2800); NMR data
see Table 2 and ESI;† HRESIMS, [M + Na]+, observed m/z
401.0734, calculated 401.0728 for C19H23O379BrNa, Δ =
+1.5 ppm.
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Hamigeran H (10). Pale yellow film; [α]20
D −70° (c 0.11,
CH2Cl2); UV (MeOH) λmax 230 nm (sh, ε 8500), 283 nm
(ε 4500); NMR data see Table 2 and ESI;† HRESIMS, [M + Na]+,
observed m/z 397.1995, calculated 397.1991 for C22H30O5Na,
Δ = +1.0 ppm.
Hamigeran I (11). Pale yellow film; [α]18
D −21° (c 0.04,
CH2Cl2); UV (MeOH) λmax 220 nm (ε 18 600), 280 nm (ε 6800);
NMR data see Table 2 and ESI;† HRESIMS, [M + Na]+, observed
m/z 419.0837, calculated 419.0834 for C19H25O479BrNa, Δ =
+0.7 ppm.
Hamigeran J (12). Pale yellow film; [α]20
−5° (c 0.30,
D
CH2Cl2); UV (MeOH) λmax 230 nm (sh, ε 14 500), 289 nm
(ε 5100); NMR data see Table 3 and ESI;† HRESIMS, [M + Na]+,
observed m/z 447.0786, calculated 447.0783 for C20H25O579BrNa, Δ = +0.7 ppm.
Hamigeran K (13). Colourless film; [α]20
−9° (c 0.08,
D
CH2Cl2); UV (MeOH) λmax 225 nm (ε 16 300), 275 nm (ε 6900),
346 nm (ε 2600); NMR data see Table 3 and ESI;† HRESIMS,
[M + Na]+, observed m/z 389.0724, calculated 389.0728 for
C18H23O379BrNa, Δ = −1.0 ppm.
10-epi-Hamigeran K (14). Colourless film; [α]20
D −14° (c 0.1,
CH2Cl2); UV (MeOH) λmax 226 nm (ε 15 200), 274 nm (ε 6300),
339 nm (ε 2700); NMR data see Table 3 and ESI;† HRESIMS,
[M + Na]+, observed m/z 389.0726, calculated 389.0728 for
C18H23O379BrNa, Δ = −0.5 ppm.
4-Bromohamigeran K (15). Colourless film; [α]25
+19°
D
(c 0.05, CH2Cl2); UV (MeOH) λmax 220 nm (ε 13 200), 279 nm
(ε 2000), 350 nm (ε 1800); NMR data see Table 3 and ESI;†
HRESIMS, [M + Na]+, observed m/z 466.9833, calculated
466.9833 for C18H22O379Br2Na, Δ = 0.0 ppm.
Hamigeran L (16). Colourless film; [α]25
+66° (c 0.27,
D
CH2Cl2); UV (MeOH) λmax 218 nm (ε 29 400), 312 nm (ε 2500);
NMR data see Table 2 and ESI;† HRESIMS, [M + Na]+, observed
m/z 435.0784, calculated 435.0783 for C19H25O579BrNa, Δ =
+0.2 ppm.
Hamigeran L 11-O-methyl ester (17). Colourless film; [α]25
D
+28° (c 0.09, CH2Cl2); UV (MeOH) λmax 218 nm (ε 40 100),
308 nm (ε 3900); NMR data see Table 2 and ESI;† HRESIMS,
[M + Na]+, observed m/z 449.0933, calculated 449.0940 for
C20H27O579BrNa, Δ = −1.6 ppm.
12-Acetoxy-13-epi-neoverrucosan-5-one (18). Colourless film;
[α]20
D +11° (c 0.17, CH2Cl2); NMR data see ESI;† HRESIMS,
[M + Na]+, observed m/z 369.2401, calculated 369.2406
for C22H34O3Na, Δ = −1.4 ppm.
Hamigeran A ethyl ester (19). Yellow film; [α]25
D −57° (c 0.10,
CH2Cl2); UV (MeOH) λmax 226 nm (ε 8100), 282 nm (ε 3800),
351 nm (ε 1800); NMR data see ESI;† HRESIMS, [M + Na]+,
observed m/z 461.0932, calculated 461.0934 for C21H27O579BrNa, Δ = −0.5 ppm.
Cell proliferation assays and chemical genomic screening
MTT cell proliferation assays were carried out in the promyelocytic leukaemic HL-60 cell line as previously described.22
Chemical genomic screens for determining genetic interactions with hamigerans B and G in S. cerevisiae followed standard methods as described.19,23
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